A comprehensive review of autoantibodies in primary Sjögren's syndrome: Clinical phenotypes and regulatory mechanisms

Journal of Autoimmunity

Volumn 51, Issue , 2014, Pages 67-74

  Kyriakidis, Nikolaos C ^a   Kapsogeorgou, Efstathia K ^a   Tzioufas, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anti La SSB; Anti Ro SSA; Autoantibodies; Salivary gland epithelial cells; Sj rgen's syndrome

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; CALRETICULIN; CARBONATE DEHYDRATASE ANTIBODY; CENTROMERE ANTIBODY; CRYOGLOBULIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; LA ANTIBODY; MICRORNA; MITOCHONDRION ANTIBODY; MUSCARINIC 3 RECEPTOR ANTIBODY; RHEUMATOID FACTOR; SMOOTH MUSCLE ANTIBODY; TOLL LIKE RECEPTOR 3; U1RNP ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; APOPTOSIS; EPITHELIUM CELL; EXOSOME; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SALIVARY GLAND; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; ANIMAL; AUTOIMMUNITY; BLOOD; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; PATHOLOGY; SJOGREN'S SYNDROME;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; IMMUNOMODULATION; PHENOTYPE; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 84901274724     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.11.001     Document Type: Review

References (93)

1. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. JAutoimmun 2012, 39:4-8.
2. Routsias J.G., Vlachoyiannopoulos P.G., Tzioufas A.G. Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. Crit Rev Clin Lab Sci 2006, 43:203-248.
3. Routsias JG, Kyriakidis N, Latreille M, Tzioufas AG. RNA recognition motif (RRM) of La/SSB: the bridge for interparticle spreading of autoimmune response to U1-RNP. Mol Med;16:19-26.
4. Yiannaki E., Vlachoyiannopoulos P.G., Manoussakis M.N., Sakarellos C., Sakarellos-Daitsiotis M., Moutsopoulos H.M., et al. Study of antibody and T cell responses in rabbits immunized with synthetic human B cell epitope analogues of La (SSB) autoantigen. Clin Exp Immunol 2000, 121:551-556.
5. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos H.M. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. JAutoimmun 2010, 34:400-407.
6. Kapsogeorgou E.K., Christodoulou M.I., Panagiotakos D.B., Paikos S., Tassidou A., Tzioufas A.G., et al. Minor salivary gland inflammatory lesions in Sjogren syndrome: do they evolve?. JRheumatol 2013, 40:1566-1571.
7. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos N.M., Moutsopoulos H.M. Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 2008, 173:1389-1396.
8. Skopouli F.N., Fox P.C., Galanopoulou V., Atkinson J.C., Jaffe E.S., Moutsopoulos H.M. Tcell subpopulations in the labial minor salivary gland histopathologic lesion of Sjogren's syndrome. JRheumatol 1991, 18:210-214.
9. Jonsson M.V., Skarstein K. Follicular dendritic cells confirm lymphoid organization in the minor salivary glands of primary Sjogren's syndrome. JOral Pathol Med 2008, 37:515-521.
10. Manoussakis M.N., Boiu S., Korkolopoulou P., Kapsogeorgou E.K., Kavantzas N., Ziakas P., et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007, 56:3977-3988.
11. Xanthou G., Tapinos N.I., Polihronis M., Nezis I.P., Margaritis L.H., Moutsopoulos H.M. CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjogren's syndrome. Clin Exp Immunol 1999, 118:154-163.
12. Manoussakis M.N., Kapsogeorgou E.K. The role of intrinsic epithelial activation in the pathogenesis of Sjogren's syndrome. JAutoimmun 2010, 35:219-224.
13. Moutsopoulos H.M. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994, 72:162-165.
14. Manoussakis M.N., Spachidou M.P., Maratheftis C.I. Salivary epithelial cells from Sjogren's syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation. JAutoimmun 2010, 35:212-218.
15. Dimitriou I.D., Kapsogeorgou E.K., Abu-Helu R.F., Moutsopoulos H.M., Manoussakis M.N. Establishment of a convenient system for the long-term culture and study of non-neoplastic human salivary gland epithelial cells. Eur J Oral Sci 2002, 110:21-30.
16. Bourazopoulou E., Kapsogeorgou E.K., Routsias J.G., Manoussakis M.N., Moutsopoulos H.M., Tzioufas A.G. Functional expression of the alpha 2-macroglobulin receptor CD91 in salivary gland epithelial cells. JAutoimmun 2009, 33:141-146.
17. Kapsogeorgou E.K., Manoussakis M.N. Salivary gland epithelial cells (SGEC): carriers of exquisite B7-2 (CD86) costimulatory molecules. JAutoimmun 2010, 35:188-191.
18. Katsiougiannis S., Kapsogeorgou E.K., Manoussakis M.N., Skopouli F.N. Salivary gland epithelial cells: a new source of the immunoregulatory hormone adiponectin. Arthritis Rheum 2006, 54:2295-2299.
19. Abu-Helu R.F., Dimitriou I.D., Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: invitro assessment of T cell-derived cytokines and Fas protein expression. JAutoimmun 2001, 17:141-153.
20. Ohlsson M., Jonsson R., Brokstad K.A. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjogren's syndrome. Scand J Immunol 2002, 56:456-469.
21. Polihronis M., Tapinos N.I., Theocharis S.E., Economou A., Kittas C., Moutsopoulos H.M. Modes of epithelial cell death and repair in Sjogren's syndrome (SS). Clin Exp Immunol 1998, 114:485-490.
22. Kapsogeorgou E.K., Abu-Helu R.F., Moutsopoulos H.M., Manoussakis M.N. Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins. Arthritis Rheum 2005, 52:1517-1521.
23. Nardi N., Brito-Zeron P., Ramos-Casals M., Aguilo S., Cervera R., Ingelmo M., et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjogren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006, 25:341-346.
24. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
25. Oke V., Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. JAutoimmun 2012, 39:77-82.
26. Yang K., Shi H.X., Liu X.Y., Shan Y.F., Wei B., Chen S., et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. JImmunol 2009, 182:3782-3792.
27. Wolin S.L., Cedervall T. The La protein. Annu Rev Biochem 2002, 71:375-403.
28. He J., Guo J.P., Ding Y., Li Y.N., Pan S.S., Liu Y., et al. Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sjogren's syndrome. Rheumatology (Oxford) 2011, 50:879-884.
29. Sommer G., Dittmann J., Kuehnert J., Reumann K., Schwartz P.E., Will H., et al. The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene 2011, 30:434-444.
30. Itoh K., Itoh Y., Frank M.B. Protein heterogeneity in the human Ro/SSA ribonucleoproteins. The 52- and 60-kD Ro/SSA autoantigens are encoded by separate genes. JClin Invest 1991, 87:177-186.
31. Schulte-Pelkum J., Fritzler M., Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009, 8:632-637.
32. Routsias J.G., Tzioufas A.G. Sjogren's syndrome-study of autoantigens and autoantibodies. Clin Rev Allergy Immunol 2007, 32:238-251.
33. Manoussakis M.N., Tzioufas A.G., Pange P.J., Moutsopoulos H.M. Serological profiles in subgroups of patients with Sjogren's syndrome. Scand J Rheumatol Suppl 1986, 61:89-92.
34. Mavragani C.P., Tzioufas A.G., Moutsopoulos H.M. Sjogren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol 2000, 123:46-57.
35. Tzioufas A.G., Wassmuth R., Dafni U.G., Guialis A., Haga H.J., Isenberg D.A., et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study. Ann Rheum Dis 2002, 61:398-404.
36. Friedman D.M., Llanos C., Izmirly P.M., Brock B., Byron J., Copel J., et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010, 62:1138-1146.
37. Fauchais A.L., Martel C., Gondran G., Lambert M., Launay D., Jauberteau M.O., et al. Immunological profile in primary Sjogren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev 2010, 9:595-599.
38. Martel C., Gondran G., Launay D., Lalloue F., Palat S., Lambert M., et al. Active immunological profile is associated with systemic Sjogren's syndrome. JClin Immunol 2011, 31:840-847.
39. Ramos-Casals M., Solans R., Rosas J., Camps M.T., Gil A., Del Pino-Montes J., et al. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008, 87:210-219.
40. Bournia V.K., Vlachoyiannopoulos P.G. Subgroups of Sjogren syndrome patients according to serological profiles. JAutoimmun 2012, 39:15-26.
41. Voulgarelis M., Tzioufas A.G. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol 2010, 6:529-537.
42. Katano K., Kawano M., Koni I., Sugai S., Muro Y. Clinical and laboratory features of anticentromere antibody positive primary Sjogren's syndrome. JRheumatol 2001, 28:2238-2244.
43. Kitagawa T., Shibasaki K., Toya S. Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjogren's syndrome. Clin Rheumatol 2012, 31:105-112.
44. Nakamura H, Kawakami A, Hayashi T, Iwamoto N, Okada A, Tamai M, etal. Anti-centromere antibody-seropositive Sjogren's syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord;11:140.
45. Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM. Anticentromere antibody positive Sjogren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther;12:R47.
46. Barcelos F., Abreu I., Patto J.V., Trindade H., Teixeira A. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjogren's syndrome. Acta Reumatol Port 2009, 34:608-612.
47. Gottenberg J.E., Mignot S., Nicaise-Rolland P., Cohen-Solal J., Aucouturier F., Goetz J., et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 2005, 64:114-117.
48. Iwamoto N., Kawakami A., Tamai M., Fujikawa K., Arima K., Aramaki T., et al. Determination of the subset of Sjogren's syndrome with articular manifestations by anticyclic citrullinated peptide antibodies. JRheumatol 2009, 36:113-115.
49. Tobon G.J., Correa P.A., Anaya J.M. Anti-cyclic citrullinated peptide antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 2005, 64:791-792.
50. Atzeni F., Sarzi-Puttini P., Lama N., Bonacci E., Bobbio-Pallavicini F., Montecucco C., et al. Anti-cyclic citrullinated peptide antibodies in primary Sjogren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008, 10:R51.
51. Bogdanos D.P., Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 2011, 412:502-512.
52. Selmi C., Meroni P.L., Gershwin M.E. Primary biliary cirrhosis and Sjogren's syndrome: autoimmune epithelitis. JAutoimmun 2012, 39:34-42.
53. Hatzis G.S., Fragoulis G.E., Karatzaferis A., Delladetsima I., Barbatis C., Moutsopoulos H.M. Prevalence and longterm course of primary biliary cirrhosis in primary Sjogren's syndrome. JRheumatol 2008, 35:2012-2016.
54. Eglen R.M. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006, 26:219-233.
55. Ishii M., Kurachi Y. Muscarinic acetylcholine receptors. Curr Pharm Des 2006, 12:3573-3581.
56. Iwabuchi Y., Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen's syndrome. Gen Pharmacol 1994, 25:123-129.
57. Nakamura T., Matsui M., Uchida K., Futatsugi A., Kusakawa S., Matsumoto N., et al. M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. JPhysiol 2004, 558:561-575.
58. Bacman S., Sterin-Borda L., Camusso J.J., Arana R., Hubscher O., Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. Clin Exp Immunol 1996, 104:454-459.
59. Li J., Ha Y.M., Ku N.Y., Choi S.Y., Lee S.J., Oh S.B., et al. Inhibitory effects of autoantibodies on the muscarinic receptors in Sjogren's syndrome. Lab Invest 2004, 84:1430-1438.
60. Koo N.Y., Li J., Hwang S.M., Choi S.Y., Lee S.J., Oh S.B., et al. Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjogren's syndrome patients. Rheumatology (Oxford) 2008, 47:828-833.
61. Kovacs L., Marczinovits I., Gyorgy A., Toth G.K., Dorgai L., Pal J., et al. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome. Rheumatology (Oxford) 2005, 44:1021-1025.
62. Roescher N., Kingman A., Shirota Y., Chiorini J.A., Illei G.G. Peptide-based ELISAs are not sensitive and specific enough to detect muscarinic receptor type 3 autoantibodies in serum from patients with Sjogren's syndrome. Ann Rheum Dis 2011, 70:235-236.
63. Dawson L.J., Allison H.E., Stanbury J., Fitzgerald D., Smith P.M. Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. Rheumatology (Oxford) 2004, 43:1488-1495.
64. Itoh Y., Reichlin M. Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 1992, 35:73-82.
65. Ono M., Ono M., Watanabe K., Miyashita Y., Inagaki Y., Ueki H. Astudy of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases. JDermatol Sci 1999, 21:183-186.
66. Nishimori I., Bratanova T., Toshkov I., Caffrey T., Mogaki M., Shibata Y., et al. Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II. JImmunol 1995, 154:4865-4873.
67. Takemoto F., Hoshino J., Sawa N., Tamura Y., Tagami T., Yokota M., et al. Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. Am J Med 2005, 118:181-184.
68. Manthorpe R., Permin H., Tage-Jensen U. Auto-antibodies in Sjogren's syndrome. With special reference to liver-cell membrane antibody (LMA). Scand J Rheumatol 1979, 8:168-172.
69. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
70. Csepregi A., Szodoray P., Zeher M. Do autoantibodies predict autoimmune liver disease in primary Sjogren's syndrome? Data of 180 patients upon a 5 year follow-up. Scand J Immunol 2002, 56:623-629.
71. Lindgren S., Manthorpe R., Eriksson S. Autoimmune liver disease in patients with primary Sjogren's syndrome. JHepatol 1994, 20:354-358.
72. Ramos-Casals M., Sanchez-Tapias J.M., Pares A., Forns X., Brito-Zeron P., Nardi N., et al. Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjogren's syndrome. JRheumatol 2006, 33:1593-1599.
73. Jonsson M.V., Szodoray P., Jellestad S., Jonsson R., Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. JClin Immunol 2005, 25:189-201.
74. Salomonsson S., Jonsson M.V., Skarstein K., Brokstad K.A., Hjelmstrom P., Wahren-Herlenius M., et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 2003, 48:3187-3201.
75. Tengner P., Halse A.K., Haga H.J., Jonsson R., Wahren-Herlenius M. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjogren's syndrome. Arthritis Rheum 1998, 41:2238-2248.
76. Ping L., Ogawa N., Sugai S. Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjogren's syndrome. Arthritis Rheum 2005, 52:573-581.
77. Okuma A., Hoshino K., Ohba T., Fukushi S., Aiba S., Akira S., et al. Enhanced apoptosis by disruption of the STAT3-IkappaB-zeta signaling pathway in epithelial cells induces Sjogren's syndrome-like autoimmune disease. Immunity 2013, 38:450-460.
78. Jerne N.K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974, 125C:373-389.
79. Routsias J.G., Tzioufas A.G. B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: tools to study the regulation of the autoimmune response. JAutoimmun 2010, 35:256-264.
80. Stea E.A., Routsias J.G., Clancy R.M., Buyon J.P., Moutsopoulos H.M., Tzioufas A.G. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006, 54:2228-2234.
81. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
82. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001, 413:732-738.
83. Nandula S.R., Dey P., Corbin K.L., Nunemaker C.S., Bagavant H., Deshmukh U.S. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. JOral Pathol Med 2013, 42:66-72.
84. Nandula S.R., Scindia Y.M., Dey P., Bagavant H., Deshmukh U.S. Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjogren's syndrome-like disease. Oral Dis 2011, 17:801-807.
85. Deshmukh U.S., Nandula S.R., Thimmalapura P.R., Scindia Y.M., Bagavant H. Activation of innate immune responses through toll-like receptor 3 causes a rapid loss of salivary gland function. JOral Pathol Med 2009, 38:42-47.
86. Ittah M., Miceli-Richard C., Gottenberg J.E., Sellam J., Eid P., Lebon P., et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008, 38:1058-1064.
87. Spachidou M.P., Bourazopoulou E., Maratheftis C.I., Kapsogeorgou E.K., Moutsopoulos H.M., Tzioufas A.G., et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome. Clin Exp Immunol 2007, 147:497-503.
88. Kelly K.M., Zhuang H., Nacionales D.C., Scumpia P.O., Lyons R., Akaogi J., et al. "Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum 2006, 54:1557-1567.
89. Kyriakidis N.C., Kapsogeorgou E.K., Gourzi V.C., Moutsopoulos H.M., Tzioufas A.G. RO52/TRIM21 expression in salivary gland epithelial cells (SGECs) is upregulated by TLR3-signaling. Annual European Congress of RHEUMATOLOGY, Madrid, Spain: Annals of the Rheumatic Diseases 2013, 78.
90. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
91. Carissimi C., Fulci V., Macino G. MicroRNAs: novel regulators of immunity. Autoimmun Rev 2009, 8:520-524.
92. Alevizos I., Alexander S., Turner R.J., Illei G.G. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome. Arthritis Rheum 2011, 63:535-544.
93. Kapsogeorgou E.K., Gourzi V.C., Manoussakis M.N., Moutsopoulos H.M., Tzioufas A.G. Cellular microRNAs (miRNAs) and Sjogren's syndrome: candidate regulators of autoimmune response and autoantigen expression. JAutoimmun 2011, 37:129-135.